Over 400 organisations across 25 countries are racing to bring these therapies to patients with otherwise untreatable diseases.
A single CAR-T dose still takes up to 33 days to manufacture, at $170,000–$220,000 per batch.
Stuart Curbishley on how adthera bio is tackling the biggest bottleneck in cell and gene therapy: getting therapies manufactured at scale.
Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.
Stuart Therapeutics is testing the first collagen mimetic peptide for dry eye disease – a novel mechanism that produced Week 1 staining gains vs. vehicle greater than any reported result for an approved therapy in their recent Phase 3.
With zero FDA-approved personalised iPSC therapies on the market, the vast majority of patients who could benefit from regenerative treatments still can’t access them.
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
The machinery that governs gene expression is being targeted to beat cancer.
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
If the disease is in the lungs, why deliver the drugs everywhere else?
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
"85% of failures are us having failed the molecule, not the molecule having not delivered."
Fresh momentum from Jefferies and a new $150 million non-dilutive financing has extended its runway into 2027.
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
Blood tests for cancer are here, and Guardant Health is leading the charge.
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Dr. Adil Ali asks Dr. John Patton (CSO) and Dan Miller (Formulation Development Lead) all about eSpraye's drug pipeline.
The story of how an Indian biotech startup slashed the cost of CAR-T from $475,000 to just $30,000 and started a revolution in global CAR-T therapy access.
